Novartis AG (NYSE:NVS)‘s stock had its “neutral” rating reiterated by analysts at JPMorgan Chase & Co. in a report released on Thursday.
NVS has been the topic of several other research reports. Vetr cut Novartis AG from a “strong-buy” rating to a “buy” rating and set a $84.66 price target on the stock. in a report on Monday, March 13th. Zacks Investment Research cut Novartis AG from a “hold” rating to a “sell” rating in a report on Tuesday, November 29th. Argus raised Novartis AG from a “hold” rating to a “buy” rating in a report on Tuesday, January 31st. Deutsche Bank AG reaffirmed a “neutral” rating on shares of Novartis AG in a report on Monday, January 9th. Finally, BNP Paribas cut Novartis AG from a “neutral” rating to an “underperform” rating in a report on Tuesday, March 7th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and six have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $83.12.
Novartis AG (NYSE:NVS) traded up 1.21% during mid-day trading on Thursday, hitting $73.62. The stock had a trading volume of 3,940,013 shares. The company has a 50-day moving average of $74.50 and a 200-day moving average of $73.40. The stock has a market cap of $174.78 billion, a price-to-earnings ratio of 26.29 and a beta of 0.73. Novartis AG has a 12-month low of $66.93 and a 12-month high of $83.58.
Novartis AG (NYSE:NVS) last posted its quarterly earnings results on Wednesday, January 25th. The company reported $1.12 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.12. The company had revenue of $12.32 billion for the quarter, compared to analysts’ expectations of $12.44 billion. Novartis AG had a return on equity of 15.37% and a net margin of 13.80%. The firm’s revenue was down 1.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.14 earnings per share. On average, analysts anticipate that Novartis AG will post $4.69 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.chaffeybreeze.com/2017/04/20/novartis-ags-nvs-neutral-rating-reaffirmed-at-jpmorgan-chase-co-updated-updated.html.
A number of hedge funds have recently made changes to their positions in NVS. Capital Investment Advisors LLC increased its position in Novartis AG by 0.9% in the third quarter. Capital Investment Advisors LLC now owns 4,025 shares of the company’s stock worth $318,000 after buying an additional 37 shares during the period. Duncker Streett & Co. Inc. increased its position in Novartis AG by 0.5% in the third quarter. Duncker Streett & Co. Inc. now owns 7,950 shares of the company’s stock worth $628,000 after buying an additional 37 shares during the period. CENTRAL TRUST Co increased its position in Novartis AG by 0.3% in the third quarter. CENTRAL TRUST Co now owns 12,857 shares of the company’s stock worth $1,016,000 after buying an additional 38 shares during the period. Schulhoff & Co. Inc. increased its position in Novartis AG by 0.6% in the third quarter. Schulhoff & Co. Inc. now owns 6,839 shares of the company’s stock worth $540,000 after buying an additional 41 shares during the period. Finally, Genesee Valley Trust Co. increased its position in Novartis AG by 1.0% in the third quarter. Genesee Valley Trust Co. now owns 4,928 shares of the company’s stock worth $389,000 after buying an additional 49 shares during the period. 9.82% of the stock is currently owned by institutional investors.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.